RBC Capital raises Moderna stock price target on Q1 beat By Investing.com

Moderna’s Q1 2026 COVID-19 revenue of $352 million beat consensus at $232 million, driven by international sales and a UK payment recognized early. The company reaffirmed full-year guidance for up to 10% revenue growth, $3 billion of R&D spending, and $1 billion of SG&A, though cash outlook was reduced after a $950 million IP settlement charge. RBC lifted its price target to $38 from $35, while noting the risk/reward remains balanced given the stock’s strong 69% six-month rally.

Analysis

The market is starting to price Moderna less as a binary vaccine story and more as a self-funded biotech platform with multiple shots on goal. That matters because the balance sheet gives management optionality to keep pushing late-stage programs without returning to capital markets, which supports a higher floor than a typical single-asset biotech even if sentiment stays lukewarm. The real equity debate is not revenue momentum; it is whether the pipeline can convert capital intensity into durable operating leverage before the current cash burn narrative reasserts itself.

Second-order, the international COVID mix suggests pricing power and partner/sovereign procurement remain a stabilizer, but also a warning sign: the P&L is still vulnerable to timing noise and one-off collections, so headline beats can mask underlying normalization risk. The settlement-related cost step-up is important because it compresses the window in which the market can underwrite multiple expansion from “cleaner” margins; if the next two quarters do not show clearer ex-COVID product traction, investors may fade every beat as non-recurring. In other words, the stock can keep grinding, but it needs a pipeline event path, not just vaccine seasonality, to justify materially higher multiples.

The contrarian takeaway is that the stock may be less overbought on fundamentals than on expectations of a near-term catalyst cascade. The August flu decision is the first hard checkpoint, but the more important inflection is whether oncology and norovirus create enough probability-adjusted revenue to offset the market’s discount for execution risk. If those programs slip, the recent rally becomes vulnerable to a multiple reset rather than a simple earnings miss, because the street is already paying for optionality that has not yet been de-risked.

Key Decisions for Investors

• Sell upside call spreads in MRNA into strength over the next 2-6 weeks; risk/reward favors fading the move because the stock already prices in a high success rate for multiple pipeline readouts while near-term catalysts are still binary.
• For event-driven longs, buy a small June/July MRNA call spread or call diagonal ahead of the flu PDUFA; the trade is only attractive if you expect a catalyst-driven re-rating into August, with defined downside versus stock ownership.
• Pair trade: long MRNA / short a lower-quality, cash-constrained pre-profit biotech basket over 1-3 months if you want to express balance-sheet quality and pipeline optionality; the thesis is that self-funding biotechs de-rate less on risk-off tape.
• If holding MRNA common, use a trailing stop or hedge with short-dated puts into the August catalyst window; the risk is a 'sell the news' reaction if approval does not immediately translate into visible commercial conviction.